ADMA Biologics: Bollinger Bands Narrowing, KDJ Death Cross on 15min Chart

ADMA Biologics's 15-minute chart has exhibited Bollinger Bands Narrowing, accompanied by a KDJ Death Cross on October 2, 2025, at 14:15. This indicates a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, which may lead to further declines in the stock's value.

Adma Biologics (ADMA) has shown notable technical indicators on its 15-minute chart, with Bollinger Bands narrowing and a KDJ Death Cross on October 2, 2025, at 14:15. These signals suggest a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further declines in the stock's value.

The Bollinger Bands narrowing indicates a decrease in volatility, which can signal a period of consolidation or a potential reversal in the stock's price trend. The KDJ Death Cross, a signal where the K line crosses below the D line, typically indicates a bearish momentum shift. This combination of signals suggests that investors should be cautious about Adma Biologics' stock price in the near term.

Analysts and investors alike are keeping a close eye on Adma Biologics' upcoming earnings disclosure. The company is predicted to post an EPS of $0.16, indicating a 6.67% growth compared to the equivalent quarter last year. The latest consensus estimate predicts revenue to be $130.1 million, showing an 8.56% increase compared to the same quarter of the previous year. For the full year, the Zacks Consensus Estimates project earnings of $0.57 per share and a revenue of $506.7 million, demonstrating changes of +16.33% and +18.82%, respectively, from the preceding year Why Adma Biologics (ADMA) Outpaced the Stock Market Today^[1].

Despite these positive earnings expectations, the technical indicators suggest a potential downturn in the stock's value. It is crucial for investors to monitor any recent modifications to analyst estimates, as positive revisions in estimates can indicate analysts' confidence in the business performance and profit potential. The Zacks Rank system, which takes estimate changes into account, currently rates Adma Biologics as a #3 (Hold) Why Adma Biologics (ADMA) Outpaced the Stock Market Today^[1].

Adma Biologics is currently trading at a Forward P/E ratio of 25.72, which is a premium compared to its industry average Forward P/E of 18.92. The Medical - Biomedical and Genetics industry, which Adma Biologics is part of, has a Zacks Industry Rank of 80, placing it in the top 33% of all 250+ industries Why Adma Biologics (ADMA) Outpaced the Stock Market Today^[1].

Investors should remain vigilant and continue to monitor the stock's performance, particularly in light of the recent technical signals. For the latest recommendations and insights, investors are encouraged to use Zacks.com to track all stock-influencing metrics.